![MCED: A New Screening Paradigm?](https://www.g2intelligence.com/wp-content/uploads/2024/05/June24.CDI_.MCED_Testing.MS-iStock-1481732551_1100x800-1080x675.jpg)
MCED: A New Screening Paradigm?
Multicancer early detection tests—and their promise of comprehensive, minimally invasive screening—are catching the eye of labs and lawmakers
Multicancer early detection tests—and their promise of comprehensive, minimally invasive screening—are catching the eye of labs and lawmakers
Regulatory expert Julie Ballard shares her first thoughts on the final rule for lab-developed tests and immediate steps for labs
How to avoid six common compliance risks involving free supplies, equipment, software, and other non-monetary compensation
Key cybersecurity points to address when working with a third party that has access to protected health information
Prenosis claims its test can detect the presence of the often deadly condition within 24 hours of a hospitalization
Cybersecurity expert outlines steps labs and other healthcare providers should take to prepare for future cyberattacks
Know where labs may fall foul of compliance requirements—and discover the actions your lab can take to mitigate the risk of noncompliance
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
This webinar will discuss steps lab leaders will need to take in the near future to ensure they are prepared for the final LDTs rule
Though not expected to drastically change the program, new component gives device makers another way to strengthen their submissions